Pulmonary Arterial Hypertension
Conditions
Brief summary
Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.
Detailed description
Pulmonary arterial hypertension is characterized by decompensated increase of pulmonary artery pressure owing to continuous progression of pulmonary vascular resistance and can ultimately cause right heart failure even death. At present, the treatment of pulmonary arterial hypertension is mainly the application of specific drug therapy. Specific drug therapy involves the three major pathways of endothelin, nitric oxide and prostacyclin. The main mechanisms of vasodilation and anti-proliferation are used to treat pulmonary arterial hypertension. However, the price of specific drug therapy is too expensive, which puts huge financial pressure on patients. Evidence shows that inflammation exists in the early stages of pulmonary arterial hypertension and anti-inflammatory treatment is effective in animal experiments. Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.
Interventions
DRUGSulfasalazine
Sulfasalazine is an anti-inflammatory and immunosuppressive drug
DRUGAmbrisentan
Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
DRUGSulfasalazine's placebo
Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
DRUGAmbrisentan's placebo
Ambrisentan's placebo is similar to Ambrisentan in form and dosage
Sponsors
RenJi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Pulmonary artery systolic pressure estimated in the most recent echocardiography examination before screening ≧40mmHg. 2. Before the study, subjects received the best traditional pulmonary arterial hypertension(PAH) treatment (such as oral Ca2+ antagonists, oxygen therapy, digoxin, diuretics, and anticoagulants), and no increase, discontinuation, or dose change at least one month before randomization. But it is allowed to stop or adjust anticoagulants, and adjust the therapeutic dose of diuretics. 3. The results of echocardiography showed that the systolic and diastolic functions of the left ventricle were normal, and there was no clinically significant left heart disease (such as mitral valve disease).
Exclusion criteria
1. Patients who have received endothelin receptor antagonists and anti-inflammatory drugs within 30 days before randomization. 2. Patients with changes in the basic PAH treatment within one month before randomization (such as addition/removal of therapeutic drugs or dose adjustment; including but not limited to oxygen, diuretics, digoxin, anticoagulants, immunosuppressants, or Ca2+ antagonists ). But we allows the discontinuation of anticoagulants or change the dose and the change of diuretic dose. 3. Patients who diagnosed with other etiology of PAH, such as portal hypertension, pulmonary vein occlusive disease, etc. 4. Patients who have a history of left heart disease including ischemic heart disease, myocardial infarction, symptomatic coronary artery disease; or trans-channel radionuclide angiography, angiography, or echocardiography as assessed by mean pulmonary capillary wedge pressure (or left ventricular end diastolic volume) ≥ 15 mmHg or left ventricular ejection fraction ≤ 40%; or systemic hypertension that cannot be effectively controlled, systolic blood pressure\> 160 mmHg or diastolic blood pressure\> 100 mmHg. 5. Patients who have a history of lung diseases, including chronic obstructive pulmonary disease, interstitial lung disease, etc. 6. Patients who have a history of blood diseases, including a history of coagulation disorders within 6 months before screening. 7. Patients who are allergic to two or more drugs or food; or are known to be allergic to one anti-inflammatory drug (steroidal or non-steroidal anti-inflammatory drug). 8. Liver function test exceeds or equals 3 times the upper limit of normal or suffering from known Child-Pugh Class C liver disease. 9. Patients with chronic renal insufficiency, and the screening creatinine value is greater than 2.5mg/dL (221μmol/L) or need dialysis. 10. Patients with other diseases or conditions that can affect the results of the research. 11. Patients who participated in other study drugs or medical devices within 30 days before screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to First Confirmed Clinical Adverse Event up to the End of Treatment | Up to end of treatment (data presented up to month 6) | Clinical adverse event was defined as death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Month 6 in 6-minute Walk Distance | Baseline to month 6 | The 6-minute walk test (6MWT) is a non-encouraged test, performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. These guidelines were provided to all sites. For patients who had never performed a 6MWT previously, a training test was required before the qualifying tests for inclusion were performed. |
| Change From Baseline to Month 6 in Inflammation Factor | Baseline to month 6 | Compose of Interleukin-6 |
| Change From Baseline to Month 6 in Echocardiography Examination | Baseline to month 6 | Assessment of pulmonary artery systolic pressure by echocardiography |
| Change From Baseline to Month 6 in Cardiac Function | Baseline to month 6 | Compose of B-type natriuretic peptide |
Countries
China
Contacts
Primary ContactJieyan Shen, PhD
Outcome results
None listed